• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Influence of IL-6 levels on patient survival in COVID-19.

作者信息

Arulkumaran Nishkantha, Snow Timothy A C, Kulkarni Adarsh, Brealey David, Rickman Hannah M, Rees-Spear Chloe, Spyer Moira J, Heaney Judith, Garr Edmund, Williams Bryan, Cherepanov Peter, Kassiotis George, Lunn Michael P, Ambler Gareth, Houlihan Catherine, McCoy Laura E, Nastouli Eleni, Singer Mervyn

机构信息

Bloomsbury Institute of Intensive Care Medicine, University College London, London WC1E 6BT, United Kingdom.

Bloomsbury Institute of Intensive Care Medicine, University College London, London WC1E 6BT, United Kingdom.

出版信息

J Crit Care. 2021 Dec;66:123-125. doi: 10.1016/j.jcrc.2021.08.013. Epub 2021 Sep 16.

DOI:10.1016/j.jcrc.2021.08.013
PMID:34537594
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8443425/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e365/8443425/ef62ec67ed19/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e365/8443425/ef62ec67ed19/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e365/8443425/ef62ec67ed19/gr1_lrg.jpg

相似文献

1
Influence of IL-6 levels on patient survival in COVID-19.白细胞介素-6水平对新型冠状病毒肺炎患者生存的影响。
J Crit Care. 2021 Dec;66:123-125. doi: 10.1016/j.jcrc.2021.08.013. Epub 2021 Sep 16.
2
Role of interleukin-6, serum ferritin, and d-dimer in hospitalized COVID-19 patients.白细胞介素-6、血清铁蛋白和 D-二聚体在住院 COVID-19 患者中的作用。
Cytokine. 2024 Dec;184:156776. doi: 10.1016/j.cyto.2024.156776. Epub 2024 Oct 8.
3
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.托珠单抗治疗 COVID-19 患者的临床结局：一项个体患者数据系统评价。
J Med Virol. 2020 Nov;92(11):2516-2522. doi: 10.1002/jmv.26038. Epub 2020 Jun 9.
4
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.呼吸功能障碍预测新冠肺炎重症肺炎和过度炎症患者对白细胞介素-1 和白细胞介素-6 阻断的反应。
Front Immunol. 2021 Apr 29;12:675678. doi: 10.3389/fimmu.2021.675678. eCollection 2021.
5
Molecular Determination of Tumor Necrosis Factor-alpha, Interleukin-8, Interleukin-10, and C-X-C Chemokine Receptor-2 Genetic Variations and their Association with Disease Susceptibility and Mortality in COVID-19 Patients.新冠病毒肺炎患者肿瘤坏死因子-α、白细胞介素-8、白细胞介素-10和C-X-C趋化因子受体2基因变异的分子测定及其与疾病易感性和死亡率的关联
Curr Genomics. 2024 Feb 23;25(1):12-25. doi: 10.2174/0113892029272497240103052359.
6
Association of Interleukin-32 and Interleukin-34 with Cardiovascular Disease and Short-Term Mortality in COVID-19.白细胞介素-32和白细胞介素-34与COVID-19患者心血管疾病及短期死亡率的关联
J Clin Med. 2023 Jan 27;12(3):975. doi: 10.3390/jcm12030975.
7
Effect of galectin-3, IL-1, IL-6 and TNF-alpha on disease prognosis and mortality in COVID-19 patients.半乳糖凝集素-3、白细胞介素-1、白细胞介素-6 和肿瘤坏死因子-α 对 COVID-19 患者疾病预后和死亡率的影响。
J Infect Dev Ctries. 2024 Sep 30;18(9.1):S33-S39. doi: 10.3855/jidc.19706.
8
Association of interleukin polymorphisms and inflammatory markers with hospitalization, survival, and COVID-19 severity in type 1 diabetes patients: A multivariate and Cox regression analysis.
Cell Mol Biol (Noisy-le-grand). 2025 Feb 2;71(1):125-134. doi: 10.14715/cmb/2025.70.1.14.
9
Serum IL-6: A potential biomarker of mortality among SARS-CoV-2 infected patients in Mexico.血清白细胞介素-6：墨西哥新冠病毒感染患者死亡的潜在生物标志物。
Cytokine. 2021 Jul;143:155543. doi: 10.1016/j.cyto.2021.155543. Epub 2021 Apr 17.
10
Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.银屑病患者接受白细胞介素-17 抑制剂治疗后感染 COVID-19、住院和死亡的风险：系统评价和荟萃分析。
Front Immunol. 2022 Oct 21;13:1046352. doi: 10.3389/fimmu.2022.1046352. eCollection 2022.

引用本文的文献

1
Differential absolute plasma IL-6 concentrations between two immunoassay platforms in intensive care unit patients with COVID-19.新冠肺炎重症监护病房患者两种免疫检测平台间白细胞介素 6 血浆绝对浓度的差异。
Biomark Med. 2023 May;17(9):459-464. doi: 10.2217/bmm-2023-0073. Epub 2023 Aug 31.
2
Biological sex is associated with heterogeneous responses to IL-6 receptor inhibitor treatment in COVID-19-A retrospective cohort study.生物性别与 COVID-19 患者对白细胞介素 6 受体抑制剂治疗的异质反应相关：一项回顾性队列研究。
Sci Rep. 2023 Aug 19;13(1):13504. doi: 10.1038/s41598-023-40744-y.
3
Protective Role of Combined Polyphenols and Micronutrients against Influenza A Virus and SARS-CoV-2 Infection In Vitro.

本文引用的文献

1
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.托珠单抗治疗新型冠状病毒肺炎：一项随机对照试验的荟萃分析、试验序贯分析和荟萃回归分析
Intensive Care Med. 2021 Jun;47(6):641-652. doi: 10.1007/s00134-021-06416-z. Epub 2021 May 21.
2
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
3
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
复合多酚与微量营养素对甲型流感病毒和新型冠状病毒2型体外感染的保护作用
Biomedicines. 2021 Nov 19;9(11):1721. doi: 10.3390/biomedicines9111721.
托珠单抗对重症或危重症 2019 冠状病毒病患者 15 天临床结局的影响：随机对照试验。
BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.
4
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.严重和危重新冠肺炎中的细胞因子升高：快速系统评价、荟萃分析，并与其他炎症综合征比较。
Lancet Respir Med. 2020 Dec;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5. Epub 2020 Oct 16.
5
Immunomodulators in COVID-19: Two Sides to Every Coin.新冠疫情中的免疫调节剂：事物皆有两面性
Am J Respir Crit Care Med. 2020 Nov 15;202(10):1460-1462. doi: 10.1164/rccm.202008-3148LE.
6
Characterization of the Inflammatory Response to Severe COVID-19 Illness.严重 COVID-19 疾病炎症反应的特征。
Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821. doi: 10.1164/rccm.202005-1583OC.